Sientra - SIEN Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SIEN shares.
View SIEN analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued 1-year target prices for Sientra's stock. Their SIEN share price forecasts range from $1.30 to $8.00. On average, they predict the company's share price to reach $5.19 in the next year. This suggests a possible upside of 1,821.3% from the stock's current price.
View analysts price targets for SIEN or view top-rated stocks among Wall Street analysts.

Sientra's stock was trading at $3.67 at the start of the year. Since then, SIEN stock has decreased by 92.6% and is now trading at $0.2699.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our SIEN earnings forecast.

Sientra, Inc. (NASDAQ:SIEN) announced its quarterly earnings data on Wednesday, November, 10th. The medical instruments supplier reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.18. The medical instruments supplier had revenue of $19.62 million for the quarter, compared to analyst estimates of $18.10 million. Sientra had a negative net margin of 76.47% and a negative trailing twelve-month return on equity of 381.27%. During the same period in the prior year, the business posted ($0.33) earnings per share.

Sientra issued an update on its third quarter 2022 earnings guidance on Wednesday, November, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $21.50 million-$22.50 million, compared to the consensus revenue estimate of $21.65 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sientra investors own include Rigel Pharmaceuticals (RIGL), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Miragen Therapeutics (MGEN), Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Micron Technology (MU) and Novavax (NVAX).

Sientra trades on the NASDAQ under the ticker symbol "SIEN."

Sientra's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.27%), BlackRock Inc. (1.56%), Parkman Healthcare Partners LLC (0.57%), Ergoteles LLC (0.34%), State Street Corp (0.27%) and Evoke Wealth LLC (0.27%). Insiders that own company stock include Andrew C Schmidt, Andrew C Schmidt, Hove Caroline F Van, Jeffrey M Nugent, Oliver Christian Bennett, Paul Sean Little, Ronald Menezes and Valerie J Miller.
View institutional ownership trends.

Shares of SIEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SIEN stock can currently be purchased for approximately $0.27.

Sientra (NASDAQ:SIEN) has a market capitalization of $17.80 million and generates $80.68 million in revenue each year. The medical instruments supplier earns $-62,480,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis.

The company employs 319 workers across the globe.

Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The official website for the company is www.sientra.com. The medical instruments supplier can be reached via phone at (805) 562-3500, via email at ir@sientra.com, or via fax at 805-562-8401.